This project was completed by Intensity. Intensity joined Secretariat on February 1, 2023.
A number of generic drug companies sought FDA approval to market generic versions of a branded ADHD drug prior to the expiration of patents covering the branded drug. The generic drug companies filed Abbreviated New Drug Applications and Paragraph IV certifications asserting that patents covering the branded drug were invalid or not infringed. In response, the branded drug company filed claims of patent infringement against the generic drug companies.
Intensity provided an expert report, deposition testimony, and trial testimony relating to an evaluation of the commercial success of patents covering the branded drug. As part of addressing patent validity, the court considered the testimony of a Intensity expert on whether the patented invention had been a commercial success.
Intensity analyzed economic issues involving market definition, commercial performance, and long-felt need in the marketplace. Intensity performed economic analysis to evaluate sales and market share of the branded drug among competing drugs in the marketplace. In addition, we organized and processed complex data and presented its findings from the data analysis at trial.
Intensity analyzed a number of economic issues to inform on whether commercial performance of the branded drug was driven by the patents-in-suit or other economic factors. These issues included pricing, discounting, profitability, marketing, and other potential drivers of sales. Intensity also evaluated the economic impact of marketing materials that FDA had found to be false and misleading to consumers.
Why Funder Forecasts Don’t Belong in Royalty Analysis
This article originally appeared on Law360 on June 24, 2025. In a recent article published by Law360, Managing Director Rick Eichmann explores the economic reasoning behind the U.S. District Court’s decision in Haptic Inc. v. Apple Inc. and why prelitigation funding forecasts should not be conflated with royalty analyses in patent litigation. Eichmann explains how models developed for […]
SFO’s ‘Cast-Iron Guarantee’ on Self-Reporting Comes With Fine Print
Ben Boorer, writing for Corporate Compliance Insights, examines the UK Serious Fraud Office’s clearest commitment yet to corporate self-reporting, offering a “cast-iron guarantee” of DPA negotiations for companies that self-report and cooperate. The guidance sets out defined timelines intended to bring greater predictability, but uncertainties remain around how much investigation is expected before reporting, what […]
Strengthening Export Control Compliance: Advanced Strategies for Third-Party Audits
This article first appeared on Law360 on July 7, 2025. In a recent Law360 article, Michael H. Huneke of Hughes Hubbard & Reed and John Rademacher and Abby Williams of Secretariat explore advanced strategies for strengthening export control compliance through improved third-party audits. U.S. technologies continue to be diverted to foreign adversaries, often through networks of resellers […]